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Introduction
Mature peripheral T-cell non-Hodgkin lymphomas (T-NHL) represent a rare, morphologically and clinically distinct group of aggressive Non-Hodgkin lymphomas in Europe. A geographic variation in frequency of these lymphomas was observed ranging from 1.5% (Vancouver, Canada) and 4.4% (Würzburg, Germany) to 18.3% (Hong Kong, China) of all NHL diagnosed in these specific regions (1) . Due to their relative rarity and histological heterogeneity, T-NHL have been the subject of only a limited number of studies investigating their biological background, therefore the pathobiology of T-NHL is poorly understood (2) .
Compared to patients with B-NHL, a more aggressive clinical course and inferior treatment outcome for patients with T-NHL has been reported in most studies (2) (3) (4) .
The only exception represents the anaplastic large-cell lymphoma (ALCL), that overexpresses the anaplastic lymphoma kinase (ALK) (2) . Promising treatment strategies for B-NHL do not generally improve T-NHL treatment (5) . Nevertheless, in younger T-NHL patients the addition of etoposide to standard CHOP therapy (cyclohexamide, doxorubicin, vincristine, prednisolon), improved response rates (4).
Several new agents have been introduced in combination with CHOP therapy and/or stem cell transplantation, but most of them still need to be assessed in prospective clinical trials and a more effective standard therapy for T-NHL has yet to be defined (6, 7) . Reliable prognostic markers are urgently needed as they would enable the definition of patient subpopulations based on biological characteristics. The use of the International Prognostic Index (IPI) factors may provide to some extent a survival prediction for patients with T-NHL, complementing histological analyses (4, 8) .
Recent investigations in global gene expression of T-NHL now provide a basis to
improve their classification and the discovery of new therapeutic targets in the future (9, 10) . Nevertheless, there is still a strong need to identify clinically applicable prognostic markers in order to improve treatment strategies.
There is evidence that the initiation or progression of lymphomas is supported by certain cytokines and chemokines, produced by lymphoma cells and/or cells in the tumor microenvironment, and their receptors (11, 12) . Cytokines regulate the magnitude and profile of immune responses. In addition they may act as paracrine or autocrine growth factors, thus supporting tumor growth and progression or can be involved in inflammatory processes (11) (12) (13) . In this context pro-and anti-inflammatory Circulating levels of soluble (s) TNFRI and sTNFRII were elevated in the majority of NHL and HL patients with relatively high variability, while remaining at low levels in healthy subjects (20, (24) (25) (26) . Therefore an increased production in lymphoma patients was suggested. Moreover, risk groups were defined according to circulating levels of TNF and the two TNFRs which significantly improved the predictive value of the IPI (20, 24, 26) , whereby circulating serum levels of sTNFRII have been found to be more important (24).
However, the sample size of previous studies was limited, and TNHL were underrepresented. Recently, IL-10 has been the focus of a number of studies (13, 27, 28) . A variety of cells including subsets of T cells, normal and neoplastic B cells or stimulated monocytes and macrophages secrete IL-10, which is part of a balanced network of immunoregulatory cytokines (reviewed in (29, 30) ). IL-10 is generally described to be an immunosuppressive and anti-inflammatory cytokine.
Consequentially, it has been found to exert anti-tumor immunity and to inhibit angiogenesis in experimental systems (31) (32) (33) . However, IL-10 is also known to promote tumor cell proliferation and survival by acting as auto-or paracrine growth factor (13, 27, 28) . Elevated IL-10 serum levels as well as defined IL-10 gene variations have been implicated in the pathogenesis and course of NHL and Hodgkin lymphoma (HL) (27, (34) (35) (36) (37) (38) (39) Furthermore, it has been revealed that IL-10 might play a role in the pathogenesis of T-NHL. IL-10 mRNA has been detected frequently in different T-cell and NK-Cell lymphomas (40, 41) . Due to its immunosuppressive function IL-10 is thought to promote growth in a murine T cell lymphoma cell line (42).
Lee and colleagues showed in an Asian cohort of 108 T-NHL patients a significant association between IL-10 gene polymorphisms and clinical outcome (43) . Patients carrying at least one allele of the ATA haplotype (IL-10-1087A/G,-824C/T,-597A/C) showed a better overall survival (OS) and failure-free survival compared to those without ATA haplotype. The authors stated that even though a definite association with the response to chemotherapy was not proven, their data imply that IL-10 may have some impact on the prognosis of T-NHL.
We have recently observed an increased risk for patients suffering from aggressive NHL that carry the gene variation IL-10-7400DelDel leading to a significantly shorter OS (44) . However, the number of peripheral T-NHL patients in this cohort was too small (n=45) to allow valid conclusions related to this lymphoma subgroup. High circulating levels of sTNFRII are a negative predictor for treatment response in T-NHL suggesting a role for TNFRs for the clinical course of T-NHL.
Methods

Patients and treatment
Research. Table 1 .
Genotyping analyses
DNA was isolated from whole-blood samples of 117 T-NHL, followed by fragment length analysis, Taqman® real-time PCR and SNPshot Assay (38, 50, 51) . according to the manufacture's instruction. The median of serum level values of soluble receptors was used as the threshold to define high and low producers. For IL-10 the detection limit of the assay 5 pg/ml was set to discriminate high and low IL-10 levels. All samples and standards were run in duplicates.
Statistical Analysis
For the analysis of polymorphisms in cytokine receptor genes 117 T-NHL patients were selected from the NHL-B1/B2 and RICOVER60 studies considering the factors of the International prognostic index (age >60 years, LDH>N, ECOG >1, stage III/IV, >1 extranodal involvement), bulky disease and B symptoms.
GENEPOP software was used for a first analysis of the data. These first analyses included tests for Hardy-Weinberg equilibrium, genotypic and allelic differentiation.
WHO grades for leukocytopenia and infection, genotypic and allelic differentiation between groups were analyzed using the χ 2 -test, and if required, Fisher´s exact test.
Event-free survival was defined as time from first day of therapy (NHL-B1/B2) or random assignment (RICOVER60) to progressive disease under therapy, or failure to achieve CR or CRu (i.e. no change or partial remission associated with additional therapy), additional therapy in excess of that prescribed in the protocol, relapse or death from any cause, whatever came first. Overall survival was defined as time from first day of therapy (NHL-B1/B2) or random assignment (RICOVER60) to death from any cause.
Patients without an event in EFS or OS were censored at the last day with valid information for the respective endpoint. EFS and overall survival were estimated according to Kaplan-Meier and compared by log-rank trend test. Multivariate analyses were performed with the use of Cox proportional hazard models to estimate hazard ratios for evolving an event. Nominal significance level was at 0.05 two-sided. We are aware of the problem of multiple comparisons and therefore have chosen to extract the most prominent aspect. Statistical analyses were performed with R-2.6.2.
Results
Defined gene variations examined in T-NHL patients
197 patients with mature nodal or extranodal biopsy confirmed T-cell or NK-cell lymphoma were included into the study (Table 1) . Based on the availability and quality of stored biomaterial, 117 T-NHL patients were eligible for respective sample preparation and genotyping analysis. Clinical and histological characteristics of T-NHL patients are summarized in Table 1 .
The effects of genetic variations were assessed in an exploratory fashion. DNA from T-NHL patients was genotyped for gene variations in the TNFRI (TNFRI-609G/T), TNFRII (TNFRII M196R), 12 gene variations in IL-10 and five IL-4R SNPs.
Allele and genotype frequencies are shown in Table 2 and supplemental Table 1 .
The Hardy-Weinberg test showed no significant differences between observed and suspected numbers of genotype frequencies.
Associations of the TNFRI-609G/T gene variations of the TNFRI gene with eventfree survival of T-NHL patients
To estimate the impact of the analyzed gene variations on treatment outcome in T-NHL patients, univariate and multivariate analysis of the OS and EFS of all 117 patients suffering from T-NHL was performed with a median observation time of 50.5 month. The 3-year OS and EFS rates were 70% (95% CI: 62-79) and 56% (95% CI: 47-65) respectively.
Univariate analysis of polymorphisms in the TNFRI and TNFRII genes revealed differences in treatment outcome, associated with TNFRI-609G/T. As shown in EFS compared to patients carrying TNFRI-609GT or TNFRI-609TT (p=0.041). A consistent but not significant trend has been observed for OS (p=0.099). The respective 3-year survival rates for patients homozygous for TNFRI-609G were longer compared to carriers of TNFRI-609TT and TNFRI-609GT and summarized within a   supplementay table (Supplemental table 2 ). While no differences in OS rates were observed for the polymorphism TNFRII M196R-T/G ( Figure 1C) , patients homozygous for the major allele TNFRII R196-T showed a trend towards shorter EFS rates (p=0.066; Figure 1D ) compared with patients carrying at least one minor allele TNFRII M196-G (TNFRII M196R-GG and TNFRII M196R-GT). Accordingly 3-year survival rates were shorter patients homozygous for TNFRII R196-T compared to carriers of TNFRII M196R-GG and TNFRII M196R-GT (Supplemental table 2 (Supplemental table 2 ). Although, the difference between patients showed a comparable tendency as described recently within a large cohort of 500 aNHL patients, the observed differences were not significant for T-NHL patients in the present study. Statistical power of these analyses was very low, due to the very low number of patients carrying IL-10 -7400DelDel (OS: p = 0.776; EFS: p=0.934) (44) .
In a recent study a protective effect of the ATA haplotype (IL-10-1087A, -824T, -597A) was shown (43) . We tested for this effect in our T-NHL cohort focusing onto the SNP IL-10-824C/T representing the ATA haplotype best. Comparing patients characterized by the presence of at least one T-allele (IL-10-824TT, IL-10-824CT) with those patients homozygous for the C-allele (IL-10-824CC), a worse clinical outcome was observed for the patients group TT&TC. However, this was not significant (p=0.178). Furthermore, no comparable trends for shorter cumulative OS or EFS, were detected for the other IL-10 gene variations analyzed (data not shown).
Multivariate analysis adjusted for the IPI factors were performed to identify gene variations with prognostic power independent of the IPI Factors. In Table 3 Multivariate analysis of IL-10-7400In/Del showed a 2.2 (OS) or 1.9 (EFS) times increased relative risk for carriers of IL-10-7400DelDel, which is close to that of having elevated LDH, higher ECOG-status or age, but was not significant in our study. However, this result is also consistent with an enhanced relative risk for carriers of IL-10-7400DelDel, which has been observed in a cohort of 500 aNHL patients (44) .
For the IL-4R gene variations no associations with EFS or OS of T-NHL patients
were observed in univariate or multivariate analyses. Therefore, the protective effect of the IL-4R I75 variant we observed recently seems to be restricted to DLBCL or B-NHL patients (45) .
Association of circulating sTNFRII levels with survival of T-NHL patients
Cytokine serum levels are parameters that could to some extent reflect the actual host-lymphoma interaction and thereby influence the prognosis of lymphoma patients. Therefore we measured circulating levels of sTNFRI, sTNFRII, IL-10 and sIL-4R in T-NHL patients by ELISA before treatment. The median of all measured serum levels of the analyzed soluble receptors was used as the respective threshold to define high and low producers. For sTNFRI the median was 1.74 ng/ml, for sTNFRII it was 2.16 ng/ml and for sIL-4R a median of 0.1035 ng/ml was calculated.
In case of IL-10 the threshold was set on 5 pg/ml, according to the detection limit.
First the analyzed gene variations were compared with high and low producers of sTNFRI, sTNFRII, IL-10 and sIL-4R. However, no significant associations were observed (data not shown).
Subsequently, OS and EFS rates of T-NHL patients were compared to high and low serum levels in univariate analyses. A strong association of circulating levels of sTNFRII with OS and EFS was observed. T-NHL patients with serum levels of TNFRII >2.16ng/ml had significantly shorter OS (p=0.003) and EFS (p=0.0007; Figure 2 A 
and B).
The 3-year survival rates for patients with circulating serum levels <2.16 ng/ml of sTNFRII were 80% (95% CI: 68-95) for OS and 68% (95% CI: 55-85) for EFS, while for patients with circulating serum levels ≥2.16 ng/ml the 3-year survival rates were 52% (95% CI: 38-71) and 38% (95% CI: 25-57) for OS and EFS, respectively.
Multivariate analyses adjusted for the IPI factors revealed enhanced relative risks for shorter survival ( Table 4 ). The relative risk for shorter OS (HR = 2.1; p=0.081) was comparable to the relative risk of having elevated LDH levels and even higher than the relative risk estimated for higher age, ECOG and Stage. The relative risk estimated for shorter EFS (HR = 2.5; p=0.012) was even higher than the relative risks for the other IPI factors.
To exclude that this is an effect caused by proportionally higher rate of ALK positive ALCL patients in the group of low producers, we performed the same analysis in a subgroup excluding all these patients. In this subgroup significantly shorter survival for patients with high sTNFRII serum levels were found in univariate analyses (OS: With respect to sTNFRI we observed a trend toward shorter survival to be associated with high circulating serum levels but this was not significant (OS: p=0.449; EFS: p=0.089; supplemental Figure 1A and B). Multivariate analyses adjusted for IPI factors revealed a slightly increased but insignificant relative risk for shorter EFS (HR=1.4; p=0.30) but not OS rates.
During the first 40 month patients with IL-10 serum levels ≥5 pg/ml seemed to relapse more often (have more events for OS or EFS) compared with those patients having <5 pg/ml IL-10 in their serum. However, at the end of the follow up both groups show the same OS and EFS. Due to the low number of patients the curves become instable at this point. The overall analysis revealed no statistical significant differences according to the IL-10 serum levels (OS: p=0.539; EFS p=0.363) (supplemental Figure 1C and D) . With respect to sIL4R levels no significant differences between sIL-4R levels and disease outcome could be observed. However, consistent with the results for DLBCL patients we observed a trend towards shorter survival associated with higher serum levels (OS: p=0.77; EFS: p=0.24; supplemental Figure 1E and F) (45) . This could reflect the fact that sIL-4R levels are of greater importance for the prediction of B-cell NHL treatment outcome than for T-NHL.
Discussion
There is increasing evidence, including our own recent work, that gene variations of cytokines and their receptors, as well as elevated circulating serum levels are associated with the susceptibility to or the clinical course of non-Hodgkin's or Hodgkin's lymphoma (19, 44, 45, 52, 53) . However, due to the relatively small number of patients, T-NHL played a minor role in these studies.
The present work was undertaken to fill this gap for T-NHLs. We focused on the investigation of SNPs within the genes coding for TNFRI, TNFRII, IL-10 and IL-4R. In addition circulating levels of IL-10 and the three soluble receptors were analyzed to answer the question whether these factors can be used as independent prognostic factors for T-NHL outcome in addition to those incorporated in the IPI. To our knowledge the present study is so far largest European T-NHL cohort analyzed in this way and the first analysis of SNPs in the TNFRI, TNFRII and IL-4R genes in T-NHL patients treated within prospective multicenter clinical trials.
We show that patients characterized by TNFRI-609GG have a better EFS compared to other patients. The multivariate analysis of the TNFRI-609G/T variation revealed a 1.76 fold increased relative risk for carriers of the T-allele to have a poor prognosis for EFS (Table 3 ). The observed relative risk is comparable to that estimated for clinical parameters, elevated LDH, higher ECOG-status or age.
Interestingly, an enhanced risk for shorter OS or disease-free survival for carriers of at least one T-allele at TNFRI-609G/T was observed in a study of 310 non-small-cell lung cancer patients (54) . In addition an association of the TNFRI-609T allele with susceptibility to hepatocellular carcinoma has been described (55) . However, in contrast to these studies, in squamous cell carcinoma the TNFRI -609TT genotype was protective (21) . This study has to be defined as exploratory. Additional studies have to prove if the TNFRI -609G/T gene variation will indeed become a prognostic 
factor for T-NHL outcome Furthermore, we observed that patients suffering from T-NHL carrying the IL-10 genotype IL-10-7400DelDel tend to have a shorter cumulative OS, although our results are not significant ( Figure 1E and F and Table 3) Up to now only one study dealt with the implications of IL-10 gene variations for patients with T-NHL, where the prognosis was significantly better for T-NHL patients carrying the ATA-haplotype (IL-10 -1087A,-824T,-597A ) with respect to OS and failure free survival (43). This was not observed in our study. The rare number of patients homozygous for ATA (n=4) showed an even worse prognosis. In addition, when analyzing patients carrying at least one allele of ATA in our study a respective better prognosis was not observed. However, a comparison with the cohort from Lee and colleagues is difficult. In contrast to Asian cohorts, where the ATA-haplotype is frequent; this haplotype is rather rare in Caucasian populations (51) . The opposing results in both studies might be caused by the pronounced differences in elevated serum lactate dehydrogenase levels (18.8% in our study, 53% in the study of Lee et al.) or in extranodal site involvement (19.7% in our study, 66% in the study of Lee et al.) that may reflect biological differences between T-NHL in Asian and Caucasian patients.
The most important observation of this study is the association of high circulation serum levels of sTNFRII with an adverse prognosis of T-NHL patients. Our observations are in line with previous studies on the influence of sTNFR levels on NHL and HL outcome (18, 20, 24, 25) and highlight the importance of sTNFRII levels for the small and very aggressive subgroup of T-NHLs, a subgroup that was underrepresented in earlier studies.
By comparing patients with elevated levels of sTNFRI or sTNFRII, we observed that approximately 80% of patients with elevated levels of TNFRII also had elevated levels of TNFRI. This is probably because similar signals of the host lead to secretion of both receptors.
The molecular mechanisms behind the associations of polymorphisms and serum levels with disease outcome are not clear and have to be elucidated in more detail.
TNF-α can act cancer promoting as well as cancer inhibiting, by either acting as an auto-or paracrine growth factor on lymphoma cells modifying the microenvironment and distant organs, causing fever, weight loss and other B-symptoms or by promoting apoptosis of malignant cells, leading to inhibition of tumor growth (15, 56) . Therefore The balance between TNF-α and its two receptors is tightly regulated. Rising levels of TNF-α in the serum induce shedding of TNFRI and especially TNFRII from the membrane. This can lead to a desensitization of the cell to TNF-α mediated signaling (57) . In healthy individuals the shedding is limited to a maximum, which might permit the elimination of excess unbound TNF-α (57). This balance might be deregulated in lymphoma patients, leading to the observation that elevated circulating levels of sTNFRI and especially sTNFRII are characteristic for NHL and HL independent from the origin of the lymphoma cells. However, it cannot not be ruled out that elevated levels of soluble cytokine receptors solely reflect an active immune response against malignant cells and is a sign for a chronic inflammation process not controlled by the host.
We are aware of the histological heterogeneity of peripheral T-NHL based on the wide variety of histologic subtypes included in our cohort, although all samples were obtained from prospective clinical trials. Therefore the results obtained in this exploratory study need to be confirmed in additional prospective trials.
In summary, we provide strong evidence that elevated levels of sTNFRII and to some extend also sTNFRI are prognostic for the outcome of T-NHL patients. We further report here for the first time that the TNFRI -609G/T gene variation can be patients with serum levels of TNFRII ≥2.16 ng/ml are considered as high and patients <2.16ng/ml as low producers. High serum levels of both receptors are associated with shorter survival periods. A highly significant association with high serum levels and shorter OS and EFS is found. P refers to the log-rank test. Patients at risk represents the number of patients which still can develop an event (OS or EFS) at defined time points. 
